PathWhiz ID | Pathway | Meta Data |
---|---|---|
PW176325View Pathway |
Brivaracetam Predicted Metabolism PathwayHomo sapiens
Metabolites of sildenafil are predicted with biotransformer.
|
Creator: Omolola Created On: December 07, 2023 at 15:06 Last Updated: December 07, 2023 at 15:06 |
PW127461View Pathway |
drug action
Brivudine Action PathwayHomo sapiens
Brivudine is a drug used to treat herpes zoster. Although not approved in the U.S. or Canada, it is approved in several European countries.
Brivudine exerts its antiviral activity by a selective inhibition at the pyrophosphate binding site on virus-specific DNA polymerases at concentrations that do not affect cellular DNA polymerases. Foscarnet inhibits the activity of DNA polymerase by competing with its substrate dGTP. Less viral proteins produced, fewer viruses can form.
|
Creator: Ray Kruger Created On: February 28, 2023 at 16:00 Last Updated: February 28, 2023 at 16:00 |
PW145533View Pathway |
drug action
Brivudine Drug Metabolism Action PathwayHomo sapiens
|
Creator: Ray Kruger Created On: October 07, 2023 at 16:01 Last Updated: October 07, 2023 at 16:01 |
PW128528View Pathway |
drug action
Brolucizumab Action PathwayHomo sapiens
Brolucizumab, also known as RTH258 or ESBA1008, is a monoclonal antibody used for the treatment of neovascular age-related macular degeneration. It functions as a vascular endothelial growth factor (VEGF) inhibitor, specifically targeting major VEGF-A isoforms (VEGF110, VEGF121, and VEGF165). By inhibiting these isoforms, brolucizumab reduces the proliferation of endothelial cells, vascularization of tissue, and permeability of blood vessels, which are processes associated with neovascular AMD. It has a relatively long duration of action, typically administered on a monthly basis. Patients should be informed about potential risks, including endophthalmitis, retinal detachment, and arterial thromboembolic events, associated with this medication.
|
Creator: Dorsa Yahya Rayat Created On: September 01, 2023 at 13:30 Last Updated: September 01, 2023 at 13:30 |
PW126603View Pathway |
drug action
Bromazepam Action PathwayHomo sapiens
Bromazepam is a short-acting benzodiazepine with intermediate onset commonly used to treat panic disorders and severe anxiety.
Bromazepam is a lipophilic, long-acting benzodiazepine and with sedative, hypnotic, anxiolytic and skeletal muscle relaxant properties. It does not possess any antidepressant qualities. Bromazepam, like other benzodiazepines, presents a risk of abuse, misuse, and dependence. According to many psychiatric experts, Bromazepam has a greater abuse potential than other benzodiazepines because of fast resorption and rapid onset of action.
Bromazepam allosterically binds on the benzodiazepine receptors in the post-synaptic GABA-A ligand-gated chloride channel in different sites of the central nervous system (CNS). This binding will result in an increase on the GABA inhibitory effects which is translated as an increase in the flow of chloride ions into the cell causing hyperpolarization and stabilization of the cellular plasma membrane, ultimately leading to a sedative-like effect.
|
Creator: Karxena Harford Created On: January 25, 2022 at 21:59 Last Updated: January 25, 2022 at 21:59 |
PW145443View Pathway |
drug action
Bromazepam Drug Metabolism Action PathwayHomo sapiens
|
Creator: Ray Kruger Created On: October 07, 2023 at 15:50 Last Updated: October 07, 2023 at 15:50 |
PW175983View Pathway |
Bromazepam Predicted Metabolism Pathway newHomo sapiens
Metabolites of Bromazepam are predicted with biotransformer.
|
Creator: Omolola Created On: November 29, 2023 at 13:00 Last Updated: November 29, 2023 at 13:00 |
PW000259View Pathway |
drug action
Bromfenac Action PathwayHomo sapiens
Bromfenac (also named Prolensa, Bromday or Xibrom) is a nonsteroidal anti-inflammatory drug (NSAID). It can be used to reduce ocular inflammation and pain after cataract surgery. Bromfenac is also a type of ophthalmic anti-inflammatory medicines. Bromfenac can block prostaglandin synthesis by the action of inhibition of prostaglandin G/H synthase 1 and 2. Prostaglandin G/H synthase 1 and 2 catalyze the arachidonic acid to prostaglandin G2, and also catalyze prostaglandin G2 to prostaglandin H2 in the metabolism pathway. Decreased prostaglandin synthesis in many animal model's cell is caused by presence of bromfenac.
|
Creator: WishartLab Created On: August 22, 2013 at 10:45 Last Updated: August 22, 2013 at 10:45 |
PW145061View Pathway |
drug action
Bromfenac Drug Metabolism Action PathwayHomo sapiens
|
Creator: Ray Kruger Created On: October 07, 2023 at 15:00 Last Updated: October 07, 2023 at 15:00 |
PW127971View Pathway |
drug action
Bromfenac NSAID Action PathwayHomo sapiens
Bromfenac is a nonsteroidal anti-inflammatory drug (NSAID) for ophthalmic use. Non-ophthalmic formulations of bromfenac were withdrawn in the US in 1998 due to cases of severe liver toxicity. The mechanism of its action is due to the ability of bromfenac to block prostaglandin synthesis by inhibiting cyclooxygenase 1 and 2 with selectivity for COX-2 over COX-1. Prostaglandins are mediators of certain kinds of intraocular inflammation. In studies performed in animal eyes, prostaglandins have been shown to produce disruption of the blood-aqueous humor barrier, vasodilation, increased vascular permeability, leukocytosis, and increased intraocular pressure.
|
Creator: Daphnee Created On: June 26, 2023 at 10:20 Last Updated: June 26, 2023 at 10:20 |